Home LiteratureArticle Details
PMID: 15007381 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Oncogene ·Vol. 23 ·No. 15 ·2004-04-08 ·Pages 2648-57

Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K

Abstract

We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.

MeSH Terms
Blotting, Western Cell Cycle Cell Cycle Proteins/biosynthesis Cell Division Cell Line, Tumor Coloring Agents/pharmacology Cyclin E/biosynthesis,genetics Cyclin-Dependent Kinase Inhibitor p21 Cyclin-Dependent Kinase Inhibitor p27 Cyclins/biosynthesis Dose-Response Relationship, Drug Electrophoresis, Polyacrylamide Gel Female G1 Phase Gene Expression Regulation, Neoplastic Humans Kinetics Lovastatin/pharmacology Ovarian Neoplasms/genetics,metabolism Precipitin Tests S Phase Tetrazolium Salts/pharmacology Thiazoles/pharmacology Time Factors Transfection Tumor Suppressor Proteins/biosynthesis
Chemicals
CDKN1A protein, human Cell Cycle Proteins Coloring Agents Cyclin E Cyclin-Dependent Kinase Inhibitor p21 Cyclins Tetrazolium Salts Thiazoles Tumor Suppressor Proteins Cyclin-Dependent Kinase Inhibitor p27 Lovastatin thiazolyl blue
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bedrosian Isabelle
Department of Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
Lu Karen H
Verschraegen Claire
Keyomarsi Khandan
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
2004-04-08
Pages
2648-57
Language
English
Region
England
NLM ID
8711562
Subset
IM
Grants
NCI NIH HHS · R01-CA87548 · United States
NCI NIH HHS · T32-CA09599-14 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com